SCHEMBL4876385

SCHEMBL4876385

CN1CCC(Sc2ccc(NS(=O)(=O)c3ccc(Br)cc3)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 2/20 0.49
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2D6 P10635 2/20 0.49
CYP2C19 P33261 2/20 0.49
HTR1A P08908 1/20 0.49
DRD2 P14416 1/20 0.49
HTR1D P28221 1/20 0.49
HTR1B P28222 1/20 0.49
HTR2A P28223 1/20 0.49
HTR2C P28335 1/20 0.49
HTR1E P28566 1/20 0.49
HTR1F P30939 1/20 0.49
HTR7 P34969 1/20 0.49
ADRA1B P35368 1/20 0.49
DRD3 P35462 1/20 0.49
HTR2B P41595 1/20 0.49
HTR4 Q13639 1/20 0.49
ALDH1A1 P00352 4/20 0.44
MAPT P10636 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4866321 0.89 ALDH1A1 (0.57) ALDH1A1MAPTMEN1ALOX12KMT2A
SCHEMBL4874458 0.89 ALDH1A1 (0.44) HTR6CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL4876689 0.88 CES1 (0.54) HTR6CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL4873695 0.88 ALDH1A1 (0.58) CYP3A4HTR2AHTR2CHTR1FALDH1A1
SCHEMBL4870984 0.86 PGR (0.48) HTR6CYP3A4HTR1AHTR7MEN1
SCHEMBL4874044 0.86 ALDH1A1 (0.62) HTR6CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL4876786 0.86 ALDH1A1 (0.56) HTR6DRD2HTR2AHTR2CDRD3
SCHEMBL6617076 0.86 ALDH1A1 (0.60) ALDH1A1MAPTMEN1KMT2AMAPK1
SCHEMBL4876622 0.85 ALDH1A1 (0.60) CYP3A4ALDH1A1MEN1KMT2AMAPK1
SCHEMBL4872638 0.83 GHSR (0.45) MAPTKMT2ATRIM24LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7408067-B2 Aza-cyclic compounds as modulators of acetylcholine receptors MERCK + CO., INC. (US) 2008-08-05 US disclosed
US-20050070520-A1 Aza-cyclic compounds as modulators of acetylcholine receptors MERCK SHARP & DOHME CORP. 2005-03-31 US disclosed
EP-1467986-A1 AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS ELI LILLY AND COMPANY (US) 2004-10-20 EP disclosed
WO-2003062224-A1 AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS ELI LILLY AND COMPANY (US) 2003-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070520-A1 Aza-cyclic compounds as modulators of acetylcholine receptors CHRNG, CHRNA4, CHRNB4 HTR6 335/4885CYP1A2 2014/4885CYP3A4 908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.